Antibiotic activities and toxicities

Musculoskeletal Infections

Volumn , Issue , 2003, Pages 495-528

  Mader, Jon T ^b   El Zaim, Haissam S ^a   Calhoun, Jason H ^a   LeFrock, Jack ^b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855698254     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (177)

1. Al Neugut, AT Ghatak, RL Miller. Anaphylaxis in the United States: an investigation into its epidemiology. Arch Intern Med 161(1):15-21:2001.
2. RD deShazo, SF Kemp. Allergic reactions to drugs and biologic agents. JAMA 278:1895-1906, 1997.
3. MDYow, LH Taber, FF Barrett, AA Mintz, GR Blankinship, GE Clark, DJ Clark. A ten-year assessment of methicillin-associated side-effects. Pediatrics 58:329-334, 1976.
4. UG Hodgkin. Antibiotics in the treatment of chronic staphylococcal osteomyelitis. South Med J 68:817-823, 1975.
5. TM Onorato, JL Axelrod. Hepatitis from intravenous high-dose oxacillin therapy. Ann Intern Med 89:497-500, 1978.
6. HC Neu. Aminopenicillins:clinical pharmacology and use in disease states. Int J Clin Pharmacol Biopharm 11:132-144, 1975.
7. HC Neu. Carbenicillin and ticarcillin. Med Clin North Am 66:61-77, 1982.
8. HC Neu, GG Garvey. Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrob Agents Chemother 8:457-462, 1975.
9. KP Fu, HC Neu. Piperacillin a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother 13:358-367, 1987.
10. MF Parry, D Folta. The in vitro activity of mezlocillin, against community hospital isolates in comparison to other penicillins and cephalosporins. J Antimicrob Chemother 11(suppl):97-102, 1983.
11. WA Kradjan, R Burger. In vivo inactivation of gentamicin by carbenicillin and ticarcillin. Arch Intern Med 140(12):1668-1670, 1980.
12. MS Chow, R Quintiliani, CU Nightingale. In vivo inactivation of tobramycin by ticarcillin:a case report. JAMA 247(5):658-659, 1982.
13. CE Halstenson, MO Wong, CS Herman, KL Heim-Duthoy, MATeal, MB Affrime, JH Kelloway, WE Keane, WM Awni. Effect of concomitant administration of piperacillin on the dispositions of isepamicin and gentamicin in patients with endstage renal disease. Antimicrob Agents Chemother 36:1832-1836, 1992.
14. GR Matzke, DR Luckham, AJ Collins, CE Halstenson. Effect of ticarcillin on gentamicin and tobramycin pharmacokinetics in a patient with end-stage renal disease. Pharmacotherapy 4(3):158-160, 1984.
15. DW Nierenberg. Drug inhibition of penicillin tubular secretion: concordance between in vitro and clinical findings. J Pharmacol Exp Ther 240(3):712-716, 1987.
16. HC Neu, KP Fu. Clavulanic acid: a novel inhibitor of b-lactamases. Antimicrob Agents Chemother 14:650-655, 1978.
17. C Reading, P Hepburn. The inhibition of staphylococcal b-lactamase by clavulanic acid. Biochem J 179:67-76, 1979.
18. MH Richmond, RB Sykes. The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol 9:31-88, 1973.
19. IW Fong, ER Engelking, WMM Kirby. Relative inactivation by Staphylococcus aureus of eight cephalosporin antibiotics. Antimicrob Agents Chemother 9:939-944, 1976.
20. WMM Kirby, C Regamey. Pharmacokinetics of cefazolin compared with other cephalosporins. J Infect Dis 128 (suppl):341-346, 1973.
21. EH Kass, DA Evans. Future prospects and past problems in antimicrobial therapy:the role of cefoxitin. Rev Infect Dis 1:1-2, 1973.
22. C Thornsberry. Review of in vitro activity of third-generation cephalosporins and other newer Beta-lactam antibiotics against clinically important bacteria. Am J Med 79(suppl 2A):14-20, 1985.
23. HC Neu, P Labthavikul. Antibacterial activity and b-lactam stability of ceftazidime, an aminothiazolyl cephalosporin potentially active against Pseudomonas aeruginosa. Antimicrob Agents Chemother 21:11-18, 1982.
24. BE Scully, HC Neu. clinical efficacy of ceftazidime: treatment of serious infection due to multiresistant pseudomonas and other Gram-negative bacteria. Arch Intern Med 144:57-62, 1984.
25. MK Buening, JS Wold, KS Israel, RB Krammer. Disulfiram-like reaction to betalactams. JAMA 245(20):2027, 1981.
26. RM Elenbaas, JL Ryan, WA Robinson, MJ Singsank, MJ Harvey, CD Klaassen. On the disulfiram-like activity of moxalactam. Clin Pharmacol Ther 32(3):347-355, 1982.
27. S Umeda, T Arai. Disulfiram-like reaction to moxalactam after celiac plexus alcohol block. Anesth Analg 64:377, 1985.
28. SS Kline, VF Mauro, RB Forney, EH Freimer, P Somani. Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia. Antimicrob Agents Chemother 31(9):1328-1331, 1987.
29. RA Fromtling, HH Gadebusch. Ethanol-cephalosporin antibiotic interactions: an animal model for the detection of disulfiram (Antabuse)-like effects. Methods Find Exp Clin Pharmacol 5(9):595-600, 1983.
30. HR Freedy, AB Cetnarowski, RM Lumish, FJ Schafer. Cefoperazone-induced coagulopathy. Drug Intell Clin Pharm 20(4):281-283, 1986.
31. D O’Donnell. Hypoprothrombinaemia associated with use of cefamandole. Aust N Z J Surg 61(6):471-472, 1991.
32. P Cristiano. Hypoprothrombinemia associated with cefoperazone treatment. Drug Intell Clin Pharm 18(4):314-316, 1984.
33. A Conjura, W Bell, JJ Lipsky. Cefotetan and hypoprothrombinemia. Ann Intern Med 108(4):643, 1988.
34. RB Sykes, DP Bonner, K Bush. Aztreonam: a synthetic monobactam active against aerobic Gram-negative bacteria. Antimicrob Agents Chemother 21:85-92, 1982.
35. V Fainstein, S Weaver, GP Bodey. Comparative in vitro study of SQ26, 776. Antimicrob Agents Chemother 21:294-298, 1982.
36. MF Parry. Aztreonam susceptibility testing: a retrospective analysis. Am J Med 88:75-115, 1990.
37. EA Swabb, SM Singhvi, MA Leitz, M Frantz, AA Sugerman. Metabolism and pharmacokinetics of aztreonam in healthy subjects. Antimicrob Agents Chemother 24:394-400, 1983.
38. JCL Mihindy, WM Scheld, ND Bolton, DA Spyker, EA Swabb, WB Bolton. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob Agents Chemother 24: 252-261, 1983.
39. WJ Simons, TJ Lee. Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli. Rev Infect Dis 7(suppl 4):S783-S788, 1085.
40. C Pribyl, R Salzer, J Beskin, RJ Haddad, B Pollock, B. Bevillile. Aztreonam in the treatment of serious orthopedic infections. Am J Med 78:51-56, 1985.
41. G Alvan, CE Nord. Adverse effects of monobactams and carbapenems. Drug Saf 12(5):305-313, 1995.
42. WC Hellinger, NS Brewer. Carbapenems and monobactams: imipenem, meropenem, and aztreonam. Mayo Clin Proc 74(4):420-434, 1999.
43. HC Neu, P Labthavikul. Comparative in vitro evaluation of N-formimidoyl thienamycin against Gram-positive and Gram-negative aerobic and anaerobic species and its 13-lactamase stability. Antimicrob Agents Chemother 21:180-187, 1982.
44. GL Drysano. An overview of the pharmacolocy of imipenem=cilastatin. J Antimicrob Chemother 18(suppl):79-92, 1986.
45. RR MacGregor, LO Gentry. Imipenem=cilastatin in the treatment of osteomyelitis. Am J Med 78:100-105, 1985.
46. ML Grayson, GW Gibbons, GM Habershaw, DV Freeman, FB Pomposelli, BI Rosenblum, E Levin, AW Karchmer. Use of ampicillin=sulbactam versus imipenem= cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 18:683-693, 1994.
47. J Zazgornik, W Schein, K Heimberger, FA Shaheen, F Stockenhuber. Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipient-synergism of side effects or drug interaction? Clin Nephrol 26(5):265-266, 1986.
48. C Bosmuller, W Steurer, A Konigsrainer, J Willeit, R Margreiter. Increased risk of central nervous system toxicity in patients treated with cyclosporin and imipenem= cilastatin. Nephron 58(3):362-364, 1991.
49. LRWiseman, AJ Wagstaff, RN Brogden, HM Bryson. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 50:73-101, 1995.
50. JR Edwards. Meropenem: a microbiological overview. J Antibicrob Chemother 36(suppl A):1-17, 1995.
51. RL Nichols, JW Smith, RW Geckler, SE Wilson. Meropenem versus imipenem= cilastatin in the treatment of hospitalized patients with skin and soft tissue infections. South Med J 88:397-404, 1995.
52. PF Reynolds. Structure, biochemistry, and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis 8:943-950, 1989.
53. JE Geraci, PE Hermans. Vancomycin. Mayo Clin Proc 58:88-91, 1983.
54. TC Sorrell, DR Packham, S Shanker, M Foldes, MR Munro. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med 97:344-350, 1982.
55. GL Archer. Antimicrobial susceptibility and selection or resistance among Staphylococcus epidermidis isolates recovered from patients with infections of indwelling foreign devices. Antimicrob Agents Chemother 14:353-359, 1978.
56. FV Cook, WE Farrar. Vancomycin revisited. Ann Intern Med 88:813-818, 1978.
57. PE Herman, MP Wilhem. Vancomycin. Mayo Clin Proc 62:901-905, 1987.
58. BR Smith, JL LeFrock. Vancomycin update. AFP 35:223-225, 1987.
59. AL Graziani, LA Lawson, GA Gibson, MA Steinberg, RR MacGregor. Vancomycin concentrations in infected and noninfected human bone. Antimicrob Agents Chemother 32:1320-1322, 1985.
60. RW Bundtzen, AU Gerber, DL Cohen, WA Craig. Postantibiotic suppression of bacterial growth. Rev Infect Dis 3:28-37, 1981.
61. H Hanberger. Pharmacodynamic effects of antibiotics: studies on bacterial, morphology, initial killing, postantibiotic effect, and effective regrowth time. Scand J Infect Dis 81 (suppl):1-52, 1992.
62. V DeBock, D Verbeelen, V Maes, J Sennesael. Pharmacokinetics of vancomycin in patients undergoing haemodialysis and haemofiltration. Nephrol Dial Transplant 4:635-639, 1989.
63. HE Nielsen, I Sorensen, HE Hansen. Peritoneal transport of vancomycin during peritoneal dialysis. Nephron 24:274-279, 1979.
64. RE Polk. Red man syndrome. Ann Pharmacother 32(7-8):840, 1998.
65. MRWallace, JR Mascola, EC Oldfield. Red man syndrome: incidence, etiology, and prophylaxis. J Infect Dis 164(6):1180-1185, 1991.
66. BF Farber, RC Moellering. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 23:138-141, 1983.
67. C Odio, GH McCracken, JD Nelson. Nephrotoxicity associated with vancomycinaminoglycoside therapy in four children. J Pediatr 105(3):491-493, 1984.
68. DJ Pauly, DM Musa, MR Lestico, MJ Lindstrom, CM Hetsko. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 10(6):378-382, 1990.
69. MY Munar, L Elzinga, R Brummett, TA Golper, WM Bennett. The effect of tobramycin on the renal handling of vancomycin. J Clin Pharmacol 31(7):618-623, 1991.
70. PF Smith, CT Taylor. Vancomycin-induced neutropenia associated with fever:similarities between two immune-mediated drug reactions. Pharmacotherapy 19(2):240-244, 1999.
71. HH Kesarwala, WJ Rahill, N Amaram. Vancomycin induced neutropenia. Lancet 1(8235):1423, 1981.
72. CE Howard, LA Adams, JL Admire, MA Chu, GL Alred. Vancomycin-induced thrombocytopenia: a challenge and rechallenge. Ann Pharmacother 31(3):315-318, 1997.
73. JC Kuruppu, TP Le, CU Tuazon. Vancomycin-associated thrombocytopenia: case report and review of the literature. Am J Hematol 60(3):249-250, 1999.
74. VL Sutter. In vitro susceptibility of anaerobes: comparison of clindamycin and other antimicrobial agents. J Infect Dis 135(suppl):7-12, 1977.
75. JL LeFrock, A Molavi. Clindamycin. Med Clinics North Am 66:103-120, 1982.
76. JD Panzer, DC Brown, WL Epstein, RL Lipson, HW Mchaffey, WH Atkinson. Clindamycin levels in various body tissues and fluids. J Clin Pharrnacol 12:259-262, 1972.
77. MS Klempner, B Styrt. Clindamycin uptake by human neutrophils. J Infect Dis 144:472-479, 1981.
78. NH Steigbigel. Erythromycin, lincomycin, and clindamycin. In: GL Mandell, RG Douglas Jr, JE Bennett, eds. Principles and Practice of Infectious Diseases. 3d ed. New York: Churchill Livingstone, 1990:308-317.
79. JL LeFrock, AS Klainer, S Chen, RB Gainer, M Omar, W Anderson. The spectrum of colitis associated with lincomycin and clindamycin therapy. J Infect Dis 131(suppl):108-115, 1975.
80. LD Becker, RD Miller. Clindamycin enhances a nondepolarizing neuromuscular blockade. Anesthesiology 45:84, 1976.
81. O al Ahdal, DR Bevan. Clindamycin-induced neuromuscular blockade. Can J Anaesth 42(7):614-617, 1995.
82. JA Best, All Marashi, LD Pollan. Neuromuscular blockade after clindamycin administration:a case report. J Oral Maxillofac Surg 57(5):600-603, 1999.
83. E Rubinstein, P Prokocimer, GH Talbot. Safety and tolerability of quinupristin= dalfopristin: administration guidelines. J Antimicrob Chemother 44(suppl A):37-46, 1999.
84. SC Piscitelli, LH Danziger, KA Rodvold. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharmacol Ther 11:137-152, 1992.
85. RE Fuller, RH Drew, JR Perfect. Treatment of vancomycin-resistant enterococci with a focus on quinupristin-dalfopristin. Pharmacotherapy 16:584-592, 1996.
86. C Chant, MJ Rybak. Quinupristin=dalfopristin (RP59500); a new streptogramin antibiotic. Ann Pharmacother 29:1022-1030, 1995.
87. RC Moellering, PK Linden, J Reinhardt, EA Blumberg, F Bompart, GH Talbot. The efficacy and safety of quinupristin=dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. Synercid Emergency Use Study Group. J Antimicrob Chemother 44:251-261, 1999.
88. KM Olsen, JA Rebuck, ME Rupp. Arthralgias and myalgias related to quinupristindalfopristin administration. Clin Infect Dis 32(4):E83-E86, 2001.
89. WH Barr, J Adir, L Garrettson. Decrease of tetracycline absorption in man by sodium bicarbonate. Clin Pharmacol Ther 12(5):779-784, 1971.
90. M Garty, A Hurwitz. Effect of cimetidine and antacids on gastrointestinal absorption of tetracycline. Clin Pharmacol Ther 28(2):203-207, 1980.
91. VX Nguyen, DE Nix, S Gillikin, JJ Schentag. Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. Antimicrob Agents Chemother 33(4):434-436, 1989.
92. CW Ford, JC Hamel, D Stapert, JK Moerman, DK Hutchinson, MR Barbachyn, GE Zurenko. Oxazolidinones: new antibacterial agents. Trends Microbiol 5(5):196-200, 1997.
93. DI Diekema, RN Jones. Oxazolidinones: a review. Drugs 59(1):7-16, 2000.
94. LD Dresser, MJ Rybak. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18:456-462, 1998.
95. CW Norden. Experimental osteomyelitis. V. Therapeutic trials with oxacillin and sisomicin alone and in combination. J Infect Dis 137:155-160, 1978.
96. SG Wilson, CC Sanders. Selection and characterization of strains of Staphylococcus aureus displaying unusual resistance to aminoglycosides. Antimicrob Agents Chemother 10:519-525, 1976.
97. CC Sanders, WE Sanders, RV Goering. In vitro studies with Sch 21420 and Sch 22591: activity in comparison with six other aminoglycosides and synergy with penicillin against enterococci. Antimicrob Agents Chemother 14:178-184, 1978.
98. LJ Riff, GG Jackson. Pharmacology of gentamicin in man. J Infect Dis 124(suppl):S98-S105, 1971.
99. GR Siber, P Echeverria, AL Smith, JW Paisley, DH Smith. Pharmacokinetics of gentamicin in children and adults. J Infect Dis 132:637-651, 1975.
100. WR Lockwood, JD Bower. Tobramycin and gentamicin concentrations in the serum of normal and anephric patients. Antimicrob Agents Chemother 3:125-129, 1973.
101. MC McHenry, JG Wagner, PM Hall, DG Vidt, TL Gavan. The pharmacokinetics of amikacin in patients with impaired renal function. J Infect Dis 134(suppl):S343-S348, 1976.
102. L Regeur, H Colding, H Jensen, JP Kampmann. Pharmacokinetics of amikacin during hemodialysis arid peritoneal dialysis. Antimicrob Agents Chemother 11:214-218, 1977.
103. P Vaudaux, FA Waldvogel. Gentimicin inactivation in purulent exudates: role of cell lysis. J Infect Dis 142:586-593, 1980.
104. SL Preston, LL Briceland. Single daily dosing of aminoglycosides. Pharmacology 15:297-316, 1995.
105. RB Drew III, GM Susig. Once daily aminoglycoside treatment. Infect Dis Clin Pract 5:12-24, 1996.
106. TC Baily, JR Little, B Littenberg, RM Reichley, WC Dunagon. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:786-795, 1997.
107. MZ Ali, MB Goetz. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:896-809, 1997.
108. R Hatala, TT Dinh, DJ Cook. Single daily dosing of aminoglycosides in immunocompromised adults: a systemic review. Clin Infect Dis 24:810-815, 1999.
109. LD Sabath, C Garner, C Wilcox, M Findland. Susceptibility of Staphylococcus aureus and Staphylococcus epidermidis to 65 antibiotics. Antimicrob Agents Chemother 9:962-969, 1976.
110. RJ Faville, DE Zaske, EL Kaplan. Staphylococcus aureus endocarditis: combined therapy with vancomycin and rifampin. JAMA 240:1963-1965, 1978.
111. G Acocella. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis 5(suppl)428-433, 1983.
112. LJ Wheat, RB Kohler, FC Luft, A White. Long-term studies of the effect of rifampin on nasal carriage of coagulase-positive staphylococci. Rev Infect Dis 5(suppl 3):S459-S462, 1983.
113. JR Horn, PD Hansten. Drug interactions with antibacterial agents. J Fam Pract 41 (1):81-90, 1995.
114. G Acocella, R Conti. Interaction of rifampicin with other drugs. Tubercle 61(3):171-177, 1980.
115. VA Strayhorn, AM Baciewicz, TH Self. Update on rifampin drug interactions, III. Arch Intern Med 157(2l):2453-2458, 1997.
116. FC Hugues, N Moore, D Julien. Interactions of antitubercular drugs. Rev Pneumol Clin 44(6):278-285, 1988.
117. N Doble, R Shaw, C Rowland-Hill, M Lush, DW Warnock, EE Keal. Pharmacokinetic study of the interaction between rifampicin and ketoconazole. J Antimicrob Chemother 21(5):633-635, 1988.
118. DP Lew, FA Waldvogel. Quinolones and osteomyelitis: state-of-the-art. Drugs 49(suppl) 2:100-111, 1995.
119. ME Ernst, EJ Ernst, ME Klepser. Levofloxacin and trovafloxacin: the next generation of fluoroquinolones. Am J Health Syst Pharm 54:2569-2584, 1997.
120. AJ Wagstaff, JA Balfour. Grepafloxacin. Drugs 53(5):817-824, 1997.
121. DR Schamberg, WI Dillon, MS Terpenning. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother 36:25233-2535, 1992.
122. HM Blumberg. D Rimland, DJ Carroll. Rapid development of ciprofloxacin resistance in methicillin-susceptible and-resistant Staphylococcus aureus. J Infect Dis 163:1279-1285, 1991.
123. DC Hooper, JS Wolfson. Fluoroquinolone antimicrobial agents. N Engl J Med 324:384-394, 1991.
124. A De Sarro, G De Sarro. Adverse reactions to fluoroquinolones: an overview on mechanistic aspects. Curr Med Chem 8(4):371-384, 2001.
125. RE Polk, Drug-drug interactions with ciprofloxacin and other fluoroquinolones. Am J Med 87(5A):76S-81S, 1989.
126. SRM Bushby. Synergy of trimethoprim and sulfonamides: history and current status. In: D Woodbine, ed. Antibiotics and Antibiosis in Agriculture. London:Butterworths, 1977: 64-81.
127. GP Wormser, GT Keusch. Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med 91:420-429, 1979.
128. TT Ward, RE Winn, AI Hartstein, DL Sewell. Observations relating to an interhospital outbreak of methicillin-resistant Staphylococcus aureus: role of antimicrobial therapy in infection control. Infect Control 2:453-459, 1981.
129. TH Self, W Evans, T Ferguson. Letter: interaction of sulfisoxazole and warfarin. Circulation 52(3):528, 1975.
130. LJ Sioris, RT Weibert, PR Pentel. Potentiation of warfarin anticoagulation by sulfisoxazole. Arch Intern Med 140(4):546-547, 1980.
131. JM Hansen, JP Kampmann, K Siersbaek-Nielsen, IB Lumholtz, M Arroe, U Abildgaard, L Skovsted. The effect of different sulfonamides on phenytoin metabolism in man. Acta Med Scand 624(suppl):106-110, 1979.
132. JB Field, M Ohta, C Boyle, A Remer. Potentiation of acetohexamide hypoglycemia by phenylbutazone. N Engl J Med 277(17):889-894, 1967.
133. SM Pond, DJ Birkett, DN Wade. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Ciin Pharmacol Ther 22(5 Pt 1):573-579 1977.
134. HS Tucker, JI Hirsch. Sulfonamide-sulfonylurea interaction. N Engl J Med 286:110, 1972.
135. JF Johnson, ME Dobmeier. Symptomatic hypoglycemia secondary to a glipizidetrimethoprim= sulfamethoxazole drug interaction. DICP 24:250, 1990.
136. DS Zaharko, H Bruckner, VT Oliverio. Antibiotics alter methotrexate metabolism and excretion. Science 166(907):887-888, 1969.
137. JE Rosenblatt, RS Edson. Metronidazole. Mayo Clin Proc 58:154-157, 1983.
138. A Molavi, JL LeFrock. Metronidazole. Am Fam Physician 24:185-187, 1981.
139. SM Finegold, GE Methisen. Metronidazole. In: GL Mandell, JE Bennett, R Dolin, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone, 1995:329-334.
140. FP Tally, CE Sullivan. Metronidazole: in vitro activity, pharmacology, and efficacy in anaerobic bacterial infections. Pharmacotherapy 1:28-38, 1981.
141. SM Finegold. Metronidazole. Ann Intern Med 93:585-587, 1980.
142. AH Lau, NP Lam, SC Piscitelli, L Wilkes, LH Danziger. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 23:328-364, 1992.
143. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (Tentative Standard: M7-T). Villanova, PA, 1983.
144. HM Ericcson, JC Sherris. Antibiotic sensitivity testing: Report of an international collaborative study. Acta Pathol Microbiol Scand 227(suppl B):1-90, 1971.
145. JG Schlicter, H MacLean. A method of determining the effective therapeutic level in the treatment of subacute bacterial endocarditis with penicillin. Am Heart J 34:209-211,1947.
146. FD Pein, KIL Vosti. Variation in performance of the serum bactericidal test. Antimicrob Agent Chemother 6:300-333, 1974.
147. LB Reller, CW Stratton. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J Infect Dis 136:196-204, 1977.
148. CW Stratton, LB Reller. Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. J Infect Dis 136:187-195, 1977.
149. JE Rosenblatt. Laboratory tests used to guide antimicrobial therapy. Mayo Clin Proc 52:611-615, 1977.
150. TR Tetzloff, GH McCracken, FD Nelson. Oral antibiotic therapy for skeletal infections in children. II. Therapy of osteomyelitis and suppurative arthritis. J Pediatr 92:485-490, 1978.
151. WA Craig. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosing regimens for broad-spectrum cephalosporins. Diagn Microb Infect Dis 22:89-96, 1995.
152. M Nishida, T Murakawer, T Kaminura. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels. Antimicrob Agents Chemother 14:6-12, 1978.
153. MN Dudley. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 91(suppl 6A):45S-50S, 1991.
154. JN Krieger, CS Dickins, M Rein. Use of a time-kill technique for susceptibility testing of Trichomonas vaginalis. Antimicrob Agents Chemother 27:332-336, 1985.
155. RD Moore, PS Lietman, CR Smith. Clinical response to aminoglycoside therapy:importance of the ratio of peak concentration to minimum inhibitory concentration. J Infect Dis 155:93-99, 1987.
156. SL Preston, GL Drusano, AL Berman, CL Fowler, AT Chow, B Dornseif, V Reichl, J Natarajan, M Corrado. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279:125-129, 1998.
157. C Olesen, FH Steffensen, GL Nielsen, L de Jong-van den Berg, J Olsen, HT Sorensen. Drug use in first pregnancy and lactation: a population-based survey among Danish women. The EUROMAP Group. Eur J Clin Pharmacol 55(2):139-144, 1999.
158. GG Briggs, RK Freeman, SJ Yaffe. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. 5th ed. Baltimore: Williams & Wilkins, 1998.
159. TT Yoshikawa. Antimicrobial therapy for elderly patients. J Am Geriatr Soc 38:1353-1372, 1990.
160. I Nilsson-Ehle, B Ljungberg. Pharmacokinetics of antimicrobial agents with aging. In: TT Yoshikawa, DC Norman, eds. Antimicrobial Therapy in Elderly Patients. New York: Marcel Dekker, 1994:33-35.
161. S Rajagopalan, TT Yoshikawa. Antibiotic selection in the elderly patient. Antibiot Clinicians 3:51-56, 1999.
162. Institute of Medicine Forum on Emerging Infections. Antimicrobial Resistance:Issues and Options, Workshop Report. PF Harrison, J Lederberg, eds. Washington, DC: National Academy Press, 1998:8-74.
163. DA Goldman, RA Weinstein, RP Wenzel, OC Tabian, RJ Dunna, RP Gaynes, J Schlosser, WJ Martone. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 275:234-240, 1996.
164. NO Fishman, PJ Brennan. Optimizing use of antimicrobial agents: pitfalls and consequences of inappropriate therapy. Journal of Clinical Outcomes Management 4:25-33, 1997.
165. DM Shales, DN Gerding, JF John Jr, WA Craig, DL Bornstein, RA Duncan, MR Eckman, WE Farrer, WH Greene, V Lorian, S Levy, JE McGowen Jr, SM Paul, J Ruskin, FC Tenover, C Watanakunakorn. Society for Health Care Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 18:275-291, 1997.
166. JE McGowen Jr, FC Tenover. Control of antimicrobial resistance in the health care system. Infect Dis Clin North Am 11:297-311, 1997.
167. MN Swartz. Use of antimicrobial agents and drug resistance (editorial). N Engl J Med 337:491-492, 1997.
168. MH Kollef, VJ Fraser. Antibiotic resistance in the intensive care unit. Ann Intern Med 134:298-314, 2001.
169. C Walsh. Molecular mechanisms that confer antibacterial drug resistance. Nature 406:775-781, 2000.
170. FC Tenover, JM Hughes. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA 275:300-304, 1996.
171. GA Jacoby, GL Archer. New mechanisms of bacterial resistance to antimicrobial agents. N Engl J Med 324:601-612, 1991.
172. PM Hawkey. The origins and molecular basis of antibiotic resistance. Br Med J 317:657-660, 1998.
173. Hospital Infection Control Practices Advisory Committee (HICPAC). Recommendations for preventing the spread of vancomycin resistance. MMWR Morb Mortal Wkly Rep 44:1-13, 1995.
174. BE Murray. Vancomycin-resistant enterococcal infections. N Engl J Med 342:710-721, 2000.
175. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992-April 2000, issued June 2000. Am J Infect Control 28:429-448, 2000.
176. M Pollack. Pseudomonas aeruginosa. In: GL Mandell, RG Douglas Jr, J Bennet, eds. Principles and Practices of Infectious Diseases. New York: Churchill Livingstone, 1990:1673-1691.
177. R Stahlmann, S Kuhner, M Shakibaei, J Flores, J Vormann, DC Van Sickle. Chondrotoxicity of ciprofloxacin in immature beagle dogs: immunochemistry, electron microscopy, and drug plasma concentrations. Arch Toxicol 73:564-572, 2000.